Key Inclusion Criteria

          1. Select advanced solid tumor for which standard therapy proven to provide clinical
             benefit does not exist, or is no longer effective

             Part A:

               -  Epithelial ovarian carcinoma (EOC)

               -  Endometrial carcinoma

               -  Castration resistant prostate cancer

               -  Non-small cell lung adenocarcinoma

               -  Papillary thyroid carcinoma

               -  Malignant mesothelioma (pleural or peritoneal)

               -  Gastroesophageal adenocarcinoma

               -  Squamous cell carcinoma of the head and neck

             Part B and Part C:

               -  Platinum-resistant EOC (including fallopian tube or primary peritoneal cancer)

               -  Endometrial carcinoma

               -  Gastric adenocarcinoma/gastroesophageal adenocarcinoma

          2. Measurable disease

          3. ECOG status 0-1

          4. Resolution of prior-therapy-related adverse effects

          5. Minimum of 4 weeks or 5 half-lives since last dose of cancer therapy

        Key Exclusion Criteria:

          1. Previous hypersensitivity reaction to treatment with another monoclonal antibody

          2. Unresolved hypersensitivity to paclitaxel or any of its excipients (Part B only).
             Patients who have been desensitized may participate.

          3. Part C Only

               1. History of interstitial lung disease or a history of (non-infectious) pneumonitis
                  that required steroids or has current pneumonitis.

               2. History of immune mediated colitis, hepatitis, endocrinopathies, nephritis or
                  significant immune mediated skin reactions such as toxic epidermal necrolitis or
                  Stevens -Johnson Syndrome

               3. History of any autoimmune disease which required systemic therapy* in the past 2
                  years (i.e., with use of disease modifying agents, corticosteroids or
                  immunosuppressive drugs) including but not limited to: i. Inflammatory bowel
                  disease (including ulcerative colitis and Crohn's Disease) ii. Rheumatoid
                  arthritis iii. Systemic progressive sclerosis (scleroderma) iv. Systemic lupus
                  erythematosus v. Autoimmune vasculitis (e.g. Wegener's granulomatosis)
                  *Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
                  replacement therapy for adrenal or pituitary insufficiency) is not considered a
                  form of systemic treatment and is allowed)

          4. Prior treatment with a checkpoint inhibitor (anti-PD-1, PD-L1, CTLA-4 etc.) within 4
             weeks prior to the start of study drug

          5. Prior treatment with a CD47-targeted therapy

          6. Prior organ or stem cell transplant